利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.032 秒)

    COMPOSITION FOR TREATING PROSTATE CANCER (PCa)
    32.
    发明申请
    COMPOSITION FOR TREATING PROSTATE CANCER (PCa) 审中-公开
    治疗前列腺癌（PCa）的组合物

    公开(公告)号：US20170000871A1

    公开(公告)日：2017-01-05

    申请号：US15271122

    申请日：2016-09-20

    申请人： CureVac AG

    发明人： Jochen PROBST ,  Ingmar HOERR ,  Thomas LANDER

    IPC分类号： A61K39/00 ,  A61K39/39

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

    摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

    摘要翻译： 本发明涉及包含至少一种RNA的活性（免疫刺激性）组合物，优选mRNA，编码能够在哺乳动物中引发（适应性）免疫应答的至少两种（优选不同的）抗原，其中抗原选自 PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）。 本发明还涉及包含活性（免疫刺激）组合物和使用活性（免疫刺激）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的疫苗， 治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。 最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

    COMPOSITION FOR TREATING PROSTATE CANCER (PCa)
    33.
    发明申请
    COMPOSITION FOR TREATING PROSTATE CANCER (PCa) 审中-公开
    治疗前列腺癌（PCa）的组合物

    公开(公告)号：US20160303210A1

    公开(公告)日：2016-10-20

    申请号：US15198456

    申请日：2016-06-30

    申请人： CureVac AG

    发明人： Jochen PROBST ,  Ingmar HOERR ,  Thomas LANDER

    IPC分类号： A61K39/00

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

    摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

    摘要翻译： 本发明涉及包含至少一种RNA（优选mRNA）的活性（免疫刺激性）组合物，其编码至少两种（优选不同的）能够在哺乳动物中引发（适应性）免疫应答的抗原，其中所述抗原选自组 由PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）组成。 本发明还涉及包含活性（免疫刺激）组合物和使用活性（免疫刺激）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的疫苗， 治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。 最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

    NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
    35.
    发明申请
    NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT 有权

    公开(公告)号：US20220401555A1

    公开(公告)日：2022-12-22

    申请号：US17809680

    申请日：2022-06-29

    申请人： CureVac AG

    发明人： Thomas KRAMPS ,  Söhnke VOSS ,  Jochen PROBST ,  Ingmar HOERR

    IPC分类号： A61K39/39 ,  C07H21/00 ,  C12N15/117

    摘要： The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

    NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
    37.
    发明申请
    NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT 审中-公开

    公开(公告)号：US20200016264A1

    公开(公告)日：2020-01-16

    申请号：US16581017

    申请日：2019-09-24

    申请人： CureVac AG

    发明人： Ingmar HOERR ,  Jochen PROBST ,  Thomas KETTERER ,  Birgit SCHEEL

    IPC分类号： A61K39/39

    摘要： The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.

    NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN
    39.
    发明申请
    NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN 审中-公开

    公开(公告)号：US20180161422A1

    公开(公告)日：2018-06-14

    申请号：US15892356

    申请日：2018-02-08

    申请人： CureVac AG

    发明人： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

    IPC分类号： A61K39/145 ,  C12N7/00

    摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.